The Advanced Prostate Cancer Pipeline: A Continuum
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Drug development in advanced prostate cancer typically moves along a continuum, first targeting either castration-resistant (hormone-refractory) patients who have already taken the first-line chemotherapy docetaxel or the larger population of those who are chemotherapy-naïve after failing medical and surgical castration. Drugs that can reach into the hormone-sensitive prostate cancer population would reach even more patients. Below are selected drugs in late-stage development for advanced prostate cancer and their progress in the various indications.
You may also be interested in...
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.
Novo Nordisk’s Semaglutide Achieves ‘Cardiodiabesity’ Label
With Wegovy’s new indication for cardiovascular risk reduction in patients with overweight and obesity, the migration of diabetes drugs from a single disease state to address a host of interrelated conditions reaches a new milestone.